Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Maurie Markman, MD


August 22, 2022

Currently, eight genes (EGFR, ALK, ROS1, BRAF, NTRK, MET, KRAS, and RET) have therapies that have been approved by the US Food and Drug Administration (FDA). Several other genes are being targeted by drugs that are undergoing clinical trials. About 35% of patients with advanced nonsquamous NSCLC have a driver mutation targetable by an FDA-approved agent.

Learn more about targeted therapies for NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.